FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							()				1								
Name and Address of Reporting Person* Crespo Jessica				2. Issuer Name and Ticker or Trading Symbol Ocugen, Inc. [OCGN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Crespo</u>	Jessica				===	<u> </u>	<u>., 1110.</u>	[00	011						Director			10% Ov	/ner
// D		· · · · · ·	78.4° d.41 X		2 Do	ato of	Earlinet :	Tranca	otion (Mo	nth/D	av/Voor)			_ X	Officer (below)	give title		Other (s below)	pecify
(Last) (First) (Middle) C/O OCUGEN, INC.				3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023								CAO/SVP, Finance							
11 GREAT VALLEY PARKWAY				If Amendment, Date of Original Filed (Month/Day/Year)							<u> </u>	6. Individual or Joint/Group Filing (Check Applicable							
					4. lf <i>F</i>	Amen	dment, E	Date of	Original F	-iled (Month/Da	ay/Year)		6. Inc		oint/Group	Filing	(Check App	licable
(Street) MALVE	RN PA	A	19355											3	Form fil	•		rting Persor	
															Form fil Person	ed by Mor	e than	One Repor	ting
(City)	(S	tate)	(Zip)																
		Та	ble I - Non	-Deriva	ative	Sec	urities	s Acq	uired,	Disp	osed c	of, or I	3ene	eficially	Owned				
Date				Execution Date, h/Day/Year) if any		Execution Date,		Code (Instr.					Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	()	A) or O)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock ⁽¹⁾ 01/03				01/03	3/2023			A		122,9	22,951 A		\$0	163,391			D		
			Table II - I								sed of, onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Inst		on E			6. Date Exercisabl Expiration Date (Month/Day/Year)		of Securities		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Cod	de V	((A)		Date Exercisabl		xpiration ate	Title	O N	mount r lumber f Shares		(Instr. 4)	-11(a)		
Option (Right to Buy)	\$1.25	01/03/2023		A		1	147,638		(2)	0	1/03/2033	Comm		47,638	\$0	147,63	38	D	

Explanation of Responses:

- 1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Ocugen Inc.'s (the "Company's") common stock. The RSUs vest annually in three equal installments commencing on January 3, 2024, subject to continued service with the Company on the applicable vesting dates. The RSUs will be settled on each applicable vesting date in shares of the Company's
- 2. The option vests annually in equal installments over three years commencing on January 3, 2024, subject to continued service with the Company on the applicable vesting dates.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney

/s/ Jessica Crespo

01/05/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OCUGEN, INC.

POWER OF ATTORNEY

Know all by these present, that I, the undersigned director and/or officer of Ocugen, Inc., a Delaware corporation (the "Company"), hereby constitute and appoint Shankar Musumuri as my true and lawful attorney-infact and agent, with full power to act, with full power of substitution and resubstitution, for me and in my name, place and stead, in any and all capacities:

- (i) to execute and file for and on behalf of the undersigned any reports on Forms 3, 4 and 5 (including any amendments thereto and any successors to such Forms) with respect to ownership acquisition or disposition of securities of the Company that the undersigned may be required to file with the U.S. Securities and Exchange Commission (the "SEC") in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules promulgated thereunder;
- to execute and file for and on behalf of the undersigned any voluntary filings under Section 16(a) of the Exchange Act;
- to request electronic filing codes from the SEC by filing the Form ID (including amendments thereto) and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to file such reports electronically;
- (iv) to prepare, file, and submit any documents or reports that may be required under SEC Rule 144 to permit the undersigned to sell Company common stock without registration under the Securities Act of 1933, as amended (the "<u>Securities Act</u>") in reliance on Rule 144 as amended from time to time; or
- (v) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16(a) of the Exchange Act or the Securities Act. The Company will use all reasonable efforts to apprise the undersigned of applicable filing requirements for purposes of Section 16(a) of the Exchange Act or the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact. This Power of Attorney revokes and replaces any prior Power of Attorney executed by the undersigned with respect to the ownership, acquisition or disposition of securities of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September $16,\,2022.$

/s/ Jessica Crespo

Name: Jessica Crespo